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Abstract
Background: Depressive symptoms are common in individuals suffering from severe somatic conditions. There is a
lack of interventions and evidence-based interventions aiming to reduce depressive symptoms in patients with
severe somatic conditions. The aim of the NEVERMIND project is to address these issues and provide evidence by
testing the NEVERMIND system, designed to reduce and prevent depressive symptoms in comparison to treatment
as usual.
Methods: The NEVERMIND study is a parallel-groups, pragmatic randomised controlled trial to assess the
effectiveness of the NEVERMIND system in reducing depressive symptoms among individuals with severe somatic
conditions. The NEVERMIND system comprises a smart shirt and a user interface, in the form of a mobile
application. The system is a real-time decision support system, aiming to predict the severity and onset of
depressive symptoms by modelling the well-being condition of patients based on physiological data, body
movement, and the recurrence of social interactions. The study includes 330 patients who have a diagnosis of
myocardial infarction, breast cancer, prostate cancer, kidney failure, or lower limb amputation. Participants are
randomised in blocks of ten to either the NEVERMIND intervention or treatment as usual as the control group.
Clinical interviews and structured questionnaires are administered at baseline, at 12 weeks, and 24 weeks to assess
whether the NEVERMIND system is superior to treatment as usual. The endpoint of primary interest is Beck
Depression Inventory II (BDI-II) at 12 weeks defined as (i) the severity of depressive symptoms as measured by the
BDI-II. Secondary outcomes include prevention of the onset of depressive symptoms, changes in quality of life,
perceived stigma, and self-efficacy.
Discussion: There is a lack of evidence-based interventions aiming to reduce and prevent depressive symptoms in
patients with severe somatic conditions. If the NEVERMIND system is effective, it will provide healthcare systems
with a novel and innovative method to attend to depressive symptoms in patients with severe somatic conditions.
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Background
Depressive disorders are one of the leading causes of the
burden of disease globally. It is the third leading cause of
disability worldwide [1] with an estimated one-year
prevalence of depression of approximately 3% in the
general population [2]. This increases significantly in in-
dividuals with severe somatic conditions as there is a
high likelihood of developing a comorbid mental illness.
The prevalence of depressive symptoms in patients who
have suffered acute myocardial infarction (MI) is esti-
mated at 14% [3] while the prevalence in individuals
with chronic kidney disease can range between 26 and
39% [4]. Depressive symptoms are defined as symptoms
experienced by patients as identified with self-reported
or rater-based scales. Depression, as confirmed with a
clinical diagnosis and/or identified with ICD codes, in
patients with chronic kidney disease has a prevalence
that ranges between 21 and 22.8% [4], and between 3
and 28% in cancer patients depending on the cancer
type and treatment phase [5]. However, in reality, these
estimates are likely to be higher as depression is often
under-reported and under-detected [6]. Moreover, these
estimates do not account for other comorbidities, which
have been shown to increase the risk of depression. A
review of the literature on chronic conditions and co-
morbid depression found 1.7 increased odds of depres-
sion in patients with more than one chronic illness
compared to patients with only one chronic illness [7].
This added burden of disease increases the strain felt
by the patient, impacting the outcome of the primary
disease [8] as well as quality of life (QoL) [2], and
thereby can result in a reduction in the management of
symptoms [6]. A meta-analysis assessing the impact of
depression on mortality after MI indicated that patients
who develop depression after MI are at a 13% increased
risk of subsequent cardiac events and 22% increased risk
of all-cause mortality [9]. In addition to the burden on
the patient, there is an added burden on the healthcare
system. It has been estimated that cancer patients with
comorbid depression have a 32% higher healthcare
expenditures and are more likely to use emergency care
compared to patients who do not have comorbid
depression [10].
Research has shown that while this double burden of
disease is common in patients with severe somatic con-
ditions, little is done to prevent the progression of de-
pression and other mental disorders. The standard
general practitioner’s guidelines for patients diagnosed
with any severe somatic condition are to provide informa-
tion to patients about improving diet, physical activity,
and psychological well-being [11] to prevent subsequent
illnesses. However, patients often do not adhere to these
guidelines [12]. Moreover, severe somatic conditions gen-
erally require considerable lifestyle changes and without
proper guidance, this can be very difficult for the patient,
especially with concurrent depressive symptoms. Cur-
rently, in most European Union (EU) healthcare systems,
treatment for patients with serious somatic conditions
does not incorporate any preventive methods or early
diagnosis of the onset of comorbid depressive symptoms.
The NEVERMIND system, which stands for NEurobe-
havioural predictiVE and peRsonalised Modelling of de-
pressIve symptoms duriNg primary somatic Conditions
with ICT-enabled self-management procedures, aims to
fill this gap and give patients more control over their
mental and physical wellbeing. The NEVERMIND pro-
ject comprises a research consortium of nine different
centres in six countries that include Spain, Sweden,
Germany, Portugal, United Kingdom and the coordin-
ation centre in Italy. The feasibility of the NEVERMIND
project is based on a previously funded EU project, PSY-
CHE, where a multiparametric monitoring system based
on a sensorised shirt and a smartphone was used to
gather physiological and behavioural data of patients af-
fected by mood disorders [13, 14]. The NEVERMIND
system collects physiological data and psychometric data
to assess the risk of developing depressive symptoms. It
also contains interactive online cognitive-behavioural
therapy (CBT) modules, which are offered to patients
based on their symptoms of depression. It is anticipated
that the NEVERMIND system will encourage patients to
become more self-reliant, engage more in self-care be-
haviours, use CBT techniques, and increase their confi-
dence in their ability to carry out daily life activities. All
these factors should combine and contribute to a new
self-image of a patient and aid in reducing depressive
symptoms as well as improving the overall quality of life
for the patient.
Objectives
The primary objective is to assess the effectiveness of
the NEVERMIND system in reducing depressive symp-
toms in patients with a somatic condition in comparison
to treatment as usual (TAU). Secondary objectives are
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the effectiveness of the NEVERMIND system in prevent-
ing new symptoms of depression, improving quality of
life, perceived stigma, and self-efficacy.
Methods
Trial design
The study is a multicentre randomised (1:1) control,
parallel-group pragmatic trial conducted in Italy and
Portugal that will assess the effectiveness of the NEVER-
MIND system compared to TAU. Patients will be re-
cruited at three clinical centres; Pisa and Turin in Italy
and Lisbon in Portugal. It is hypothesised that the
NEVERMIND system is superior to TAU. The study will
be conducted according to the CONSORT guidelines for
randomised controlled parallel, non-pharmacologic trials
[15, 16]. The study design is illustrated in Table 1.
Enrolment including eligibility screening and random-
isation into either the intervention or control group took
place since November 2017, and enrolment will end in
December 2019. Baseline assessments were conducted
after randomisation and 12-week post-intervention and
24-week post intervention assessments were conducted.
The study is planned to end in March 2020.
Participants
The target sample for each group (intervention and con-
trol) is 165 participants, 330 participants in total. The
clinical centres selected are those in which the scientific
partners are affiliated. Patients from the clinics are re-
ferred to the study by their treating physicians, who are
also responsible for the patients throughout the trial.
Inclusion criteria
Eligible participants are adults aged 18 or older with a
diagnosis of one of five following somatic conditions:
MI; breast cancer; prostate cancer; kidney failure; and
leg amputees. The participants must also be proficient in
the language of the country where recruited.
Table 1 Flow diagram of the study design
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 Patients with myocardial infarction are included if
there is a diagnosis of (MI) type I including chest
pain for more than 20 min (or equivalent
symptoms), acute ECG alterations, and a diagnostic
increase of myocardial necrosis biomarkers.
 Breast cancer patients are recruited either at stage
II, III or IV.
 Prostate cancer patients are recruited either at stage
II, III or IV.
 Kidney failure patients are recruited if they are in a
stable clinical condition with chronic kidney failure
of stages III, IV, and V as defined by the KDOQI
guidelines. This corresponds to an estimated
glomerular filtration rate (eGFR) below 60 mL/min/
1.73 m2 of body-surface area.
 Amputee patients are recruited if they have had a
lower limb amputation at any level and are within
the 6 months post-surgical intervention.
Exclusion criteria
Patients are excluded if they have a past diagnosis of
a major psychiatric disorder other than depression.
These psychiatric disorders include bipolar disorder,
psychosis, and suicidality. Therefore, a diagnosis of
depression as a disorder or depressive symptoms is
not an exclusion criterion. Moreover, patients are ex-
cluded if they have had any recent and active severe
suicidality as assessed by the Paykel Suicide Scale [17]
or if they have been in treatment with a stable drug
therapy for less than two months. Patients are also
excluded if they have any cognitive impairment, such
as dementia. Moreover, individuals are excluded if
they have been involved in other structured psycho-
logical treatments involving mindfulness, CBT, other
relaxation techniques, or other structured psychother-
apy within the three months preceding enrolment. An
individual is also ineligible if they have participated or
are currently participating in any clinical trial includ-
ing but not limited to pharmacological trials that
might interfere with the study objectives. A lack of
capability to participate in study procedures including
giving consent will also result in ineligibility. Finally,
individuals are ineligible if they demonstrate an in-
ability to use Smartphone technology, especially touch
screen interaction and basic maintenance procedures
of the devices (e.g. includes charging, switching on
and off, reading notifications, making calls, and send-
ing and receiving text messages). Patients’ ability to
use Smartphone technology was assessed by asking
patients whether they are able to use smartphones to
check and send emails.
All patients that meet the inclusion criteria are asked
to participate after a comprehensive explanation of the
study. Patients provide written consent following the
guidelines set by the local ethics committee. Once the
patients have consented, they are randomised to either
the intervention group or the control group. Subse-
quently, they are asked to complete the baseline ques-
tionnaire. The primary outcome is assessed at 12-weeks
after baseline assessment, and a follow-up assessment
occurs at 24 -weeks.
Setting and location
Participants are recruited from three different locations;
Turin and Pisa in Italy and Lisbon in Portugal. Kidney
disease patients are recruited from the Cisanello Univer-
sity Hospital, University of Pisa, Italy. Breast and pros-
tate cancer patients are recruited from the following
centres within the Piedmont Oncological Network, at
San Luigi Gonzaga University Hospital, Turin, Italy and
Breast Unit-Oncology Department and Urology Depart-
ment at Città della Salute e della Scienza University
Hospital, Turin, Italy. Myocardial infarction patients are
recruited from the Cardiology Department at the Santa
Maria Hospital, Lisbon. Patients with lower limb ampu-
tations are recruited at the Rehabilitation Department at
the Santa Maria Hospital, Lisbon. Each of the centres
will recruit 75 patients, except for the Rehabilitation de-
partment in Santa Maria Hospital which will recruit 30
patients with lower limb amputations. The departments
in Turin and Lisbon are the main departments for the
region, thus, patients come from all over the region to
the clinical centres in Turin and Lisbon.
Intervention group
The intervention group will receive the NEVERMIND
system in addition to TAU, which is described in detail
in the next section. The NEVERMIND system is a multi-
faceted, two-component system that comprises a smart
shirt and a user interface, in the form of a mobile appli-
cation, to put patients at the centre of their health man-
agement. The system is a real-time decision support
system, aiming to predict the severity and onset of de-
pressive symptoms by modelling the well-being condi-
tion of patients based on physiological data, body
movement, and the recurrence of social interactions.
The interface monitors the patient’s mental health
daily and treats mental health issues as they arise. If a
user displays symptoms of depression, they are directed
to different levels of treatment in the application. Fur-
ther targeted advice and care is provided if the user dis-
plays symptoms of depression, anxiety, or stress, either
through targeted mindfulness or through the online cog-
nitive behavioural therapy programme, Deprexis, pro-
vided by Gaia AG [18].
The user interface also includes an Avatar and a
speech monitoring feature to synthetize the system’s
messages. In addition, the interface can be
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personalised to suit the patient’s dietary requirements,
exercise recommendations and preferences to provide
lifestyle guidance to improve their physical health tai-
lored to their primary somatic condition. This is set
up by the treating physician who also enters medical
details including weight, blood pressure, and type of
condition into the system. Several components are readily
available to the patient upon receiving the system (Fig. 1).
Lifestyle factors included in the application include diet
tips, including recipes, and information about physical ac-
tivity, including practice exercises. Moreover, there is a
section on sleep hygiene and two mindfulness practices per
day, either 10 or 25min long, which can be chosen by the
patient.
The smart shirt collects physiological data (biomedical
data) including electrocardiogram (ECG), accelerometer
data, and respiration data, from which biomedical fea-
tures are extracted based on signal processing tech-
niques. These features are from three categories:
movement dynamics, ECG-heart rate variability, and res-
piration dynamics.
The patients are encouraged to use the shirt as much
as they like but must use it for a minimum of twice a
week. The combined data from the interface and the
shirt will trigger different responses encouraging patients
to perform or alter activities and lifestyle choices to re-
duce the occurrence and severity of depressive symp-
toms based on their likelihood of developing depressive
symptoms. Based on the general state of the patients,
they can be directed to different levels of care as out-
lined below.
The levels of care (LC) are:
 LC0: Positive feedback for individuals who are
managing their mental health and well-being well.
 LC1: Behavioural advice for those showing initial
symptoms of depression, anxiety, or stress.
 LC2: Targeted mindfulness if mild or moderate
symptoms of depression, anxiety, or stress.
 LC3: Online cognitive behavioural therapy, Deprexis,
for those with moderate or severe symptoms of
depression, anxiety, or stress.
 LC4: The treatment team will be contacted if patient
displays severe symptoms of depression or insomnia
for several days in a row.
 LC5: Emergency information and contact of the
treatment team if the patient has suicidal intent.
If patients are not responding to a specific treatment
and are still reporting depressive symptoms after four
weeks, they will be asked if they wish to change to an-
other LC. All patients will receive the NEVERMIND sys-
tem for 12 weeks. Furthermore, each patient in the
intervention group will receive a medical consultation
regarding diet, physical activity, sleep, and an introduc-
tory session to mindfulness.
To encourage the use of the system and to measure
adherence, the system has a compliance monitoring sys-
tem. If a patient is inactive for three days, that is, not an-
swering the daily questions for three days, a reminder
will be sent to the patient. If the user is inactive for
seven days, that is not using the system for seven days,
the user will receive another reminder and the treatment
team will be notified, and they will contact the user to
ask the reason for inactivity. If the reason for inactivity
Fig. 1 Components freely available to the patients without activation
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is the inability to manage their depressive symptoms, the
users will be referred to further treatment.
Control group
The control group will receive TAU per the standard
guidelines at the respective clinics. In the Nephrology
ward at the Pisa University Hospital, patients undergo
clinical consultations with physicians regularly. The fre-
quency is based on the type of disease and stage of dis-
ease of each patient. For patients in pre-dialysis, the visit
is scheduled monthly, for patients in dialysis, the visit
takes place before every dialysis session, often three
times a week. During the visit, an evaluation of mood
and anxiety symptoms is performed. If patients report a
change in mood or an increase in anxiety level, a visit
with a psychiatrist is scheduled within one week. If ne-
cessary, medication is prescribed for patients for the
relevant psychiatric symptomatology which is compat-
ible with the clinical status of the patient.
In the clinics in Turin, TAU in terms of preventing
and treating comorbid mental illness consists of stand-
ard clinical management. This includes clinical inter-
views with the oncologist and eventual referral to the
consultation-liaison service, providing assessment, and, if
necessary, medications or brief psychological support or
both.
The Santa Maria Hospital in Lisbon is a tertiary care
unit which has no specific protocol for treating mental
health problems. There is a liaison psychiatrist and a li-
aison psychologist in each of the clinical departments
with whom a patient can meet on request. However,
treatment for mental ill-health is usually given to pa-
tients at the primary care level within the local hospital.
Patients receiving psychiatric consultation and medica-
tion for depression are retained in the trial.
Standardisation of intervention administration
Each patient participating in the intervention group
receives the standardised NEVERMIND system. All
components provided are managed at a central level.
The smart shirt and the docking station are distrib-
uted by Smartex, and patients are issued the same
smartphone with the same user interface. The smart
shirt undergoes quality control before it is distributed
to the patients. This is done by sending the data
through the docking station to the server where the
data quality control is checked by looking at the qual-
ity of signals received at the docking station. The
smartphone is set up so that patients can only use it
for the NEVERMIND application. All clinicians and
other care providers in both the intervention and
control groups are informed to perform TAU only.
Outcomes
Primary outcome
Hypothesis: NEVERMIND will significantly decrease the
level of depressive symptoms in the intervention group
in comparison to TAU in the control group;
Outcome measure: the severity of depressive symp-
toms as measured by the Beck Depression Inventory II
(BDI-II) at T12 (12-weeks post baseline assessment).
Secondary outcomes
Secondary outcomes to be measured include general
well-being, patient self-efficacy management of primary
somatic condition, perceived stigma, prevention of de-
pressive symptoms, and sustainability of the effect of
NEVERMIND at 24-weeks post-baseline assessment.
Evaluation procedures
Data will be collected at baseline, at 12 and 24 weeks
using self-report questionnaires. Moreover, there will be
a clinical interview at baseline and at each follow-up.
The presence of a psychiatric diagnosis according to
DSM-V criteria will also be evaluated during the inter-
view. DSM diagnosis are ascertained by an interview
with a psychiatrist at baseline.
The scales that will be administered at baseline and at
each follow-up evaluation include the following rater-
based and self-report scales:
 the Beck Depression Inventory II (BDI-II) which
measures depressive symptoms [19]
 the Hamilton Rating Scale for Depression (HAM-D)
which measures depressive symptoms [20]
 the Depression, Anxiety and Stress Scale (DASS-21)
which measures depressive, anxiety, and stress
symptoms [21]
 the Hamilton Rating Scale for Anxiety (HAM-A)
which measures anxiety symptoms [22]
 WHO Well-being Scale (WHO-5) which evaluates
mood, vitality, and general interests [23]
 the Paykel Suicide Scale (PSS) which determines
suicidal ideation and behaviour [17]
 the Chronic Illness Anticipated Stigma Scale (CIASS)
which measures perceived stigma [24]
 the Self-Efficacy for Managing Chronic Disease Scale
which evaluates self-efficacy in managing a chronic
disease [25]
 the Neuro-QoL (Quality of Life in Neurological
Disorders) Satisfaction with Social Roles and
Activities (8-item) which assesses satisfaction with
daily life when living with a chronic illness [26]
 the Brief Illness Perception Questionnaire which
assesses illness perception [27]
 the Self-Compassion Scale (Short Form) which
measures self-compassion [28]
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 the Rapid Assessment of Physical Activity (RAPA)
which assesses levels of physical activity [29]
The following socio-demographic data will be col-
lected at baseline: age, sex, education, marital status, em-
ployment, socioeconomic status, living arrangement, and
nationality.
Sample size
The NEVERMIND system was newly developed and
is tested in this study for the first time. Therefore, we
could not base the sample size calculations on a pre-
viously measured effect size. We estimated the sample
size based on a previous study that evaluated the ef-
fectiveness of Deprexis in reducing depressive symp-
toms among patients with somatic disorders [30]. A
very similar effect size was also found in a meta-
analysis that looked at the effectiveness of Deprexis
for depressive symptoms in different settings [18].
The sample size was calculated to detect a similar re-
duction in depressive symptoms (d = 0.54), where a
linear mixed model analysis will be used with a power
of 80%, two groups, an intercorrelation coefficient of
0.5 and a significance level of 0.05 (sistas-package
[31] and lme4-package [32] for the primary outcome.
According to power calculations performed with R
[33] for the proposed linear mixed model analysis,
110 patients were estimated. Based on the recruit-
ment criteria, which do not stipulate depressive symp-
toms as an inclusion criterium, we acknowledge that
not all patients will exhibit depressive symptoms at
recruitment. Therefore, the sample size was adjusted
to account for this. We assume that at least 1/3 of
the subjects in the sample of patients with chronic
conditions will have depressive symptoms at baseline.
In order to reach the desired sample size of 110 pa-
tients with depression or depressive symptoms, a
sample of 330 subjects who complete the study is re-
quired to have adequate power to detect medium ef-
fects. A drop-out rate of 20% has been accounted for
by adjusting the recruitment process.
Recruitment
Patients will be given the opportunity to either partici-
pate in this trial or not. However, each clinical centre is
within a hospital where a wide spectrum of patients with
severe somatic conditions are treated and would give us
the ideal platform to recruit participants.
Randomisation
Sequence generation & allocation concealment
Participants are randomly assigned following randomisa-
tion procedures to either the intervention group or the
control group. Block randomisation is used to ensure an
equal number of patients in the intervention and control
group at each site. The block randomisation randomizes
patients in the control and treatment group in blocks of
size ten. This is necessary as each clinical centre treats
different somatic conditions, and these should be equally
distributed between the two groups. Randomisation is
centralized and carried out by an electronic system de-
veloped by UPM (Universidad Politécnica de Madrid) in
collaboration with KI (Karolinska Institutet). This is
done to conceal the randomisation from the researchers
involved in enrolment and assessment.
Once the patient has met the eligibility criteria and is
enrolled in the study, he/she will complete the baseline
assessment. The clinician will then connect to a web
page and obtain a randomly generated code to be
assigned to the patient. The patient will be assigned to
either the control group or the intervention group ac-
cording to the code.
Blinding
Blinding of patients and treating physicians to treatment
allocation is not possible. The clinical psychologists who
evaluate the patients at baseline and the two follow-up
assessments are, however, different from those who ran-
domise and allocate the patients to either the interven-
tion or control group as well as provide the intervention
group about the NEVERMIND system. All evaluators
are blinded to the group allocation. Any incidence of
unblinding is reported to and recorded by the respective
centres.
Statistical analysis
Intention-to-treat (ITT) analysis will be carried out,
which hypothesises the superiority of the NEVERMIND
system in reducing depressive symptoms in comparison
to TAU. A linear mixed model will be used in order to
use all available data of each subject and choose an ap-
propriate covariance structure reflecting the potential
dependence due to repeated measures. In order to ac-
count for the repeated measurements, the baseline mea-
sures will be adjusted for in the model [30, 34]. This
increases statistical power, accounts for regression to-
wards the mean, and has been recommended for longi-
tudinal analysis of RCTs [35, 36]. Therefore, the ITT for
the primary outcome (BDI-II score at 12-weeks) will be
used as recommended for statistical analysis of clinical
trials by the European Medicines Agency (EMA; codes
CPMP/ ICH/363/96 and CPMP/EWP/2863/99). Group
(intervention and control), disease type, and hospital will
be included as fixed factors.
Comparison of demographic and clinical characteris-
tics at baseline between subjects of varying primary som-
atic conditions and clusters as well as between
intervention and control group will be examined. In case
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of imbalances of some characteristics, explorative sub-
group analyses will be performed.
If a difference between ITT and per-protocol analysis
is observed, more weight will be given to the ITT ana-
lysis, which is seen as the primary analysis. If the
NEVERMIND system does not show superiority effect
over treatment as usual for the ITT analysis, we will look
at the extent of usage of the different components of the
NEVERMIND system. Additionally, secondary analyses
of the primary outcome will include per-protocol evalua-
tions and examine the preventive effect of the NEVER-
MIND system on the incidence of depression (sensitivity
analysis). Analyses of the other secondary outcomes
(quality of life, perceived stigma and self-efficacy) will be
examined in a similar manner.
Loss to follow-up will be handled through multiple
imputations [37] if the missingness is below the rec-
ommended rate of missingness and the data structure
allows for it as recommended by Jakobsen and col-
leagues [37]. Otherwise, inverse probability weighting
[38] will be utilized. In case of loss to follow-up, ob-
servations are only imputed for missing outcomes at
24-weeks (12-weeks after the end of the intervention)
by imputing the observation recorded at 12-weeks.
No imputation will be performed for the primary out-
come at the primary endpoint (T12). Sensitivity ana-
lyses will be conducted to test the robustness of the
results by conducting complete-case and last observa-
tion carried forward analyses [30, 34, 35]. If a loss to
follow-up occurs after one follow-up (at 12-weeks),
the last observation will be carried out to subsequent
follow-ups (from 12-weeks to 24-weeks).
Data monitoring
The trial does not have a data monitoring committee
(DMC) as the study leaders at each centre oversee each
of their respective centres, while the project coordinator
manages both the scientific and administrative aspects of
NEVERMIND without a need of a DMC. Furthermore,
the NEVERMIND centre at KI is responsible for the de-
sign and the coordination of the RCT, but each centre is
responsible for overseeing data collection at their re-
spective centre. However, there is an external review
board that oversees the procedures of the trial. The
study leaders will communicate regularly with the other
members as well as the project coordinator regarding
data collection, and the project coordinator ensures
smooth internal and external communications. There
are no plans to conduct an interim analysis.
Potential risks and harms
The risks associated with using the NEVERMIND appli-
cation are minimal. If participants exceed a certain
threshold in terms of depressive symptoms, anxiety, or
suicidal ideation while using the application, they are
immediately and automatically referred to a Case Man-
ager (CM), which is a dedicated mental health worker
employed at the clinical department where the NEVER-
MIND system is used. The CM will conduct several
evaluations and refer the patient to a healthcare provider
if a referral is needed. The CM will periodically contact
the patient to monitor the effectiveness of the referral
for up to six months.
Trial status
The trial began enrolment in December 2017. Recruit-
ment will be completed by March 2020. The trial has been




Despite the high prevalence of depression among pa-
tients with severe somatic conditions, there are very few
interventions available to treat comorbid depression and
none, to our knowledge, to prevent depression in these
patients. The present study will provide evidence of
whether the NEVERMIND system is an effective inter-
vention in treating depression. If proven effective, the
NEVERMIND system will significantly reduce the excess
encumbrance posed by comorbid mental ill-health in pa-
tients with severe somatic conditions.
Firstly, the burden of disease felt by the patient would
decrease, as they will now have the tools to help prevent
mental health problems from occurring and will also be
able to treat any depressive symptoms if they arise. The
NEVERMIND system also provides guidance for lifestyle
modifications required by the primary somatic condition,
which may not be straightforward. This empowerment
helps patients by providing a sense of control over their
mental and physical health. Moreover, it can result in a
perceived decreased burden for caregivers and the
healthcare system. Patients using the NEVERMIND sys-
tem do not need to rely on their caregivers as much, for
they have a guidance system they can use instead of pla-
cing the demand on the caregiver. The NEVERMIND
system also acts as a support system to primary health-
care, resulting in reduced health care visits as the overall
health of the patient will improve.
Furthermore, the NEVERMIND system is a novel and
innovative technology that has the ability to influence
the use of technology in healthcare, as the system could
in the future be adapted and used in many different set-
tings. The system could be expanded to include a range
of other conditions that have a high prevalence of de-
pressive symptoms such as other cancers including pan-
creatic cancer or lung cancer, where the prevalence of
depressive symptoms is estimated between 33 and 50%
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for pancreatic cancer [39] and between 11 and 44% for
lung cancer. The system could also be adapted to in-
clude other conditions such as Human Immunodefi-
ciency Virus (HIV), where depression prevalence is
estimated between 22 and 45% [40]. In addition to using
NEVERMIND for other conditions with a high preva-
lence of depression or depressive symptoms, the central
machine learning could be adapted to be used in other
contexts, such as in a holistic approach to the treatment
of obesity or as a healthy weight management system.
There is also the potential to develop the system so it
can be available on different platforms such as convert-
ing the user interface to a smartwatch application or an
application on tablet computers.
Limitations
This RCT is designed as a pilot study to assess the
NEVERMIND system as a proof of concept of its effect-
iveness, and the methods and study plan have several limi-
tations. First and foremost, patients with and without the
same primary conditions are recruited in different centres
where the TAU is not consistent. This puts a limitation
on the results of the effectiveness of the NEVERMIND
system as we do not have a standardized control group.
Secondly, there is an implication for cluster confounding.
We will adjust the analyses for recruitment centre, but the
recruited sample does not allow us to stratify the sample
by somatic condition, country or clinic of recruitment.
Another limitation was the method used to assess the abil-
ity to use Smartphone technology in the intervention
group. This was assessed by asking patients if they were
able to check and send emails using a smartphone, and
not through a validated questionnaire. The inability of
some patients to use the NEVERMIND might have an in-
fluence on the extent of its effectiveness. Similarly, pa-
tients who have been part of a pharmacological trial in the
past were excluded with the intention of looking at the full
effect of the NEVERMIND system without contamination.
However, this might have excessively restricted the inclu-
sion criteria. Thirdly, complete blinding is not achievable
in this study. Even if different evaluators have been allo-
cated to different groups of patients, we cannot ensure
that incidents of unblinding do not happen. However, all
incidents of unblinding are being recorded and will be re-
ported with the results of the study. Lastly, the authors ac-
knowledge that the results of this trial will provide an
initial indication about the effectiveness of the NEVER-
MIND system and that more research will be needed in
the future to validate and replicate the results of this study
in specific categories of patients. However, if the NEVER-
MIND system will be effective in reducing depressive
symptoms in patients with a severe somatic condition, the
results of this study have future implications for a wide
range of stakeholders including patients, physicians, and
the healthcare system.
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